Class IIa HDACs: From important roles in differentiation to possible implications in tumourigenesis

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 9, 2011, Pages 1833-1846

  Clocchiatti, Andrea ^a   Florean, Cristina ^a   Brancolini, Claudio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Apoptosis; Cancer; Chromatin; Differentiation; Epigenetic; HDAC4; HDAC5; HDAC7; HDAC9; MEF2; RUNX2

Indexed keywords

HISTONE DEACETYLASE;

ANIMAL; BIOLOGICAL MODEL; CELL DIFFERENTIATION; CELL TRANSFORMATION; CHEMISTRY; HUMAN; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MODELS, BIOLOGICAL;

MUS;

EID: 80052180405     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01321.x     Document Type: Review

References (145)

1. Campos EI, Reinberg D. Histones: annotating chromatin. Annu Rev Genet. 2009; 43: 559-99.
2. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26: 5420-32.
3. Hodawadekar SC, Marmorstein R. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene. 2007; 26: 5528-40.
4. de Ruijter AJ, van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003; 370: 737-49.
5. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol. 2005; 25: 2873-84.
6. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009; 10: 32-42.
7. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008; 9: 206-18.
8. Fischle W, Dequiedt F, Fillion M, et al. Human HDAC7 histone deacetylase activity is associated with HDAC3in vivo. J Biol Chem. 2001; 276: 35826-35.
9. Fischle W, Dequiedt F, Hendzel MJ, et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell. 2002; 9: 45-57.
10. Wang AH, Yang XJ. Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol Cell Biol. 2001; 21: 5992-6005.
11. McKinsey TA, Zhang CL, Olson EN. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol Cell Biol. 2001; 21: 6312-21.
12. Miska EA, Karlsson C, Langley E, et al. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J. 1999; 18: 5099-107.
13. Grozinger CM, Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA. 2000; 97: 7835-40.
14. Kao HY, Downes M, Ordentlich P, et al. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev. 2000; 14: 55-66.
15. Wang AH, Kruhlak MJ, Wu J, et al. Regulation of histone deacetylase 4 by binding of 14-3-3 proteins. Mol Cell Biol. 2000; 20: 6904-12.
16. Liu Y, Randall WR, Schneider MF. Activity-dependent and -independent nuclear fluxes of HDAC4 mediated by different kinases in adult skeletal muscle. J Cell Biol. 2005; 168: 887-97.
17. McKinsey TA, Zhang CL, Lu J, et al. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 2000; 408: 106-11.
18. Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002; 110: 479-88.
19. Dequiedt F, Martin M, Von Blume J, et al. New role for hPar-1 kinases EMK and C-TAK1 in regulating localization and activity of class IIa histone deacetylases. Mol Cell Biol. 2006; 26: 7086-102.
20. Carnegie GK, Soughayer J, Smith FD, et al. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell. 2008; 32: 169-79.
21. Paroni G, Cernotta N, Dello Russo C, et al. PP2A regulates HDAC4 nuclear import. Mol Biol Cell. 2008; 19: 655-67.
22. McKinsey TA, Zhang CL, Olson EN. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA. 2000; 97: 14400-5.
23. Kao HY, Verdel A, Tsai CC, et al. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J Biol Chem. 2001; 276: 47496-507.
24. Chawla S, Vanhoutte P, Arnold FJ, et al. Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J Neurochem. 2003; 85: 151-9.
25. Davis FJ, Gupta M, Camoretti-Mercado B, et al. Calcium/calmodulin-dependent protein kinase activates serum response factor transcription activity by its dissociation from histone deacetylase, HDAC4. Implications in cardiac muscle gene regulation during hypertrophy. J Biol Chem. 2003; 278: 20047-58.
26. Zhang CL, McKinsey TA, Olson EN. Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol. 2002; 22: 7302-12.
27. Backs J, Backs T, Bezprozvannaya S, et al. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol Cell Biol. 2008; 28: 3437-45.
28. Hanks SK. Genomic analysis of the eukaryotic protein kinase superfamily: a perspective. Genome Biol. 2003; 4: 111-7.
29. McKinsey TA. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc Res. 2007; 73: 667-77.
30. Zugaza JL, Sinnett-Smith J, Van Lint J, et al. Protein kinase D (PKD) activation in intact cells through a protein kinase C-dependent signal transduction pathway. EMBO J. 1996; 15: 6220-30.
31. Zugaza JL, Waldron RT, Sinnett-Smith J, et al. Bombesin, vasopressin, endothelin, bradykinin, and platelet-derived growth factor rapidly activate protein kinase D through a protein kinase C-dependent signal transduction pathway. J Biol Chem. 1997; 272: 23952-60.
32. Parra M, Kasler H, McKinsey TA, et al. Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem. 2005; 280: 13762-70.
33. Wang S, Li X, Parra M, et al. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci U S A. 2008; 105: 7738-43.
34. Dequiedt F, Van Lint J, Lecomte E, et al. Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis. J Exp Med. 2005; 201: 793-804.
35. Matthews SA, Liu P, Spitaler M, et al. Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol Cell Biol. 2006; 26: 1569-77.
36. Vega RB, Harrison BC, Meadows E, et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol. 2004; 24: 8374-85.
37. Fielitz J, Kim MS, Shelton JM, et al. Requirement of protein kinase D1 for pathological cardiac remodeling. Proc Natl Acad Sci U S A. 2008; 105: 3059-63.
38. Kim MS, Fielitz J, McAnally J, et al. Protein kinase D1 stimulates MEF2 activity in skeletal muscle and enhances muscle performance. Mol Cell Biol. 2008; 28: 3600-9.
39. Berdeaux R, Goebel N, Banaszynski L, et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat Med. 2007; 13: 597-603.
40. Deng X, Ewton DZ, Mercer SE, et al. Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation. J Biol Chem. 2005; 280: 4894-905.
41. Sucharov CC, Langer S, Bristow M, et al. Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CaMKIV/PKD and PP2A. Am J Physiol Cell Physiol. 2006; 291: C1029-37.
42. Parra M, Mahmoudi T, Verdin E. Myosin phosphatase dephosphorylates HDAC7, controls its nucleocytoplasmic shuttling, and inhibits apoptosis in thymocytes. Genes Dev. 2007; 21: 638-43.
43. Martin M, Potente M, Janssens V, et al. Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis. Proc Natl Acad Sci USA. 2008; 105: 4727-32.
44. Borghi S, Molinari S, Razzini G, et al. The nuclear localization domain of the MEF2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase 4. J Cell Sci. 2001; 114: 4477-83.
45. Kozhemyakina E, Cohen T, Yao TP, et al. Parathyroid hormone-related peptide represses chondrocyte hypertrophy through a protein phosphatase 2A/histone deacetylase 4/MEF2 pathway. Mol Cell Biol. 2009; 29: 5751-62.
46. Ha CH, Kim JY, Zhao J, et al. PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2010; 107: 15467-72.
47. Ago T, Liu T, Zhai P, et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell. 2008; 133: 978-93.
48. Potthoff MJ, Wu H, Arnold MA, et al. Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest. 2007; 117: 2459-67.
49. Cernotta N, Clocchiatti A, Florean C, et al. Ubiquitin-dependent degradation of HDAC4, a new regulator of random cell motility. Mol Biol Cell. 2010; 22: 278-89.
50. Paroni G, Mizzau M, Henderson C, et al. Caspase-dependent regulation of histone deacetylase 4 nuclear-cytoplasmic shuttling promotes apoptosis. Mol Biol Cell. 2004; 15: 2804-18.
51. Kirsh O, Seeler JS, Pichler A, et al. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 2002; 21: 2682-91.
52. Liu F, Pore N, Kim M, et al. Regulation of histone deacetylase 4 expression by the SP family of transcription factors. Mol Biol Cell. 2006; 17: 585-97.
53. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006; 38: 228-33.
54. Sun Y, Ge Y, Drnevich J, et al. Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J Cell Biol. 2010; 189: 1157-69.
55. Arnold MA, Kim Y, Czubryt MP, et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell. 2007; 12: 377-89.
56. Chang S, McKinsey TA, Zhang CL, et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol. 2004; 24: 8467-76.
57. Chang S, Young BD, Li S, et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 2006; 126: 321-34.
58. Bolger TA, Yao TP. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J Neurosci. 2005; 25: 9544-53.
59. Serra C, Palacios D, Mozzetta C, et al. Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell. 2007; 28: 200-13.
60. Gregoire S, Yang XJ. Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol Cell Biol. 2005; 25: 2273-87.
61. Molkentin JD, Olson EN. Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad Sci USA. 1996; 93: 9366-73.
62. Margariti A, Xiao Q, Zampetaki A, et al. Splicing of HDAC7 modulates the SRF-myocardin complex during stem-cell differentiation towards smooth muscle cells. J Cell Sci. 2009; 122: 460-70.
63. Vega RB, Matsuda K, Oh J, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell. 2004; 119: 555-66.
64. Jeon EJ, Lee KY, Choi NS, et al. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem. 2006; 281: 16502-11.
65. Ozawa Y, Towatari M, Tsuzuki S, et al. Histone deacetylase 3 associates with and represses the transcription factor GATA-2. Blood. 2001; 98: 2116-23.
66. Watamoto K, Towatari M, Ozawa Y, et al. Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene. 2003; 22: 9176-84.
67. Liu R, Wang L, Chen G, et al. FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Res. 2009; 69: 2252-9.
68. Wang X, Feng Y, Xu L, et al. YY1 restrained cell senescence through repressing the transcription of p16. Biochim Biophys Acta. 2008; 1783: 1876-83.
69. Sucharov CC, Dockstader K, McKinsey TA. YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell. 2008; 19: 4141-53.
70. Leong H, Sloan JR, Nash PD, et al. Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha. Mol Endocrinol. 2005; 19: 2930-42.
71. van Rooij E, Fielitz J, Sutherland LB, et al. Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circ Res. 2010; 106: 155-65.
72. Karvonen U, Janne OA, Palvimo JJ. Androgen receptor regulates nuclear trafficking and nuclear domain residency of corepressor HDAC7 in a ligand-dependent fashion. Exp Cell Res. 2006; 312: 3165-83.
73. Yang Y, Tse AK, Li P, et al. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Oncogene. 2011; doi:.
74. Kurtev V, Margueron R, Kroboth K, et al. Transcriptional regulation by the repressor of estrogen receptor activityviarecruitment of histone deacetylases. J Biol Chem. 2004; 279: 24834-43.
75. Jeong BC, Hong CY, Chattopadhyay S, et al. Androgen receptor corepressor-19 kDa (ARR19), a leucine-rich protein that represses the transcriptional activity of androgen receptor through recruitment of histone deacetylase. Mol Endocrinol. 2004; 18: 13-25.
76. Wei LN, Hu X. Receptor interacting protein 140 as a thyroid hormone-dependent, negative co-regulator for the induction of cellular retinoic acid binding protein I gene. Mol Cell Endocrinol. 2004; 218: 39-48.
77. Guo L, Han A, Bates DL, et al. Crystal structure of a conserved N-terminal domain of histone deacetylase 4 reveals functional insights into glutamine-rich domains. Proc Natl Acad Sci USA. 2007; 104: 4297-302.
78. Lahm A, Paolini C, Pallaoro M, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA. 2007; 104: 17335-40.
79. Vanommeslaeghe K, De Proft F, Loverix S, et al. Theoretical study revealing the functioning of a novel combination of catalytic motifs in histone deacetylase. Bioorg Med Chem. 2005; 13: 3987-92.
80. Schuetz A, Min J, Allali-Hassani A, et al. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem. 2008; 283: 11355-63.
81. Bottomley MJ, Lo Surdo P, Di Giovine P, et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem. 2008; 283: 26694-704.
82. Zeremski M, Stricker JR, Fischer D, et al. Histone deacetylase dHDAC4 is involved in segmentation of the Drosophila embryo and is regulated by gap and pair-rule genes. Genesis. 2003; 35: 31-8.
83. van der Linden AM, Nolan KM, Sengupta P. KIN-29 SIK regulates chemoreceptor gene expressionviaan MEF2 transcription factor and a class II HDAC. EMBO J. 2007; 26: 358-70.
84. Stein GS, Lian JB, van Wijnen AJ, et al. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene. 2004; 23: 4315-29.
85. Tang H, Macpherson P, Marvin M, et al. A histone deacetylase 4/myogenin positive feedback loop coordinates denervation-dependent gene induction and suppression. Mol Biol Cell. 2009; 20: 1120-31.
86. Cohen TJ, Waddell DS, Barrientos T, et al. The histone deacetylase HDAC4 connects neural activity to muscle transcriptional reprogramming. J Biol Chem. 2007; 282: 33752-9.
87. Williams AH, Valdez G, Moresi V, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009; 326: 1549-54.
88. Kao GD, McKenna WG, Guenther MG, et al. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol. 2003; 160: 1017-27.
89. Geng L, Cuneo KC, Fu A, et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006; 66: 11298-304.
90. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268-74.
91. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007; 67: 2632-42.
92. Berns K, Hijmans EM, Mullenders J, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature. 2004; 428: 431-7.
93. Imbriano C, Gurtner A, Cocchiarella F, et al. Direct p53 transcriptional repression:in vivoanalysis of CCAAT-containing G2/M promoters. Mol Cell Biol. 2005; 25: 3737-51.
94. Basile V, Mantovani R, Imbriano C. DNA damage promotes histone deacetylase 4 nuclear localization and repression of G2/M promoters, viap53 C-terminal lysines. J Biol Chem. 2006; 281: 2347-57.
95. Cadot B, Brunetti M, Coppari S, et al. Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells. Cancer Res. 2009; 69: 6074-82.
96. Wilson AJ, Byun DS, Nasser S, et al. HDAC4 promotes growth of colon cancer cellsviarepression of p21. Mol Biol Cell. 2008; 19: 4062-75.
97. Mottet D, Pirotte S, Lamour V, et al. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene. 2009; 28: 243-56.
98. Datta J, Kutay H, Nasser MW, et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008; 68: 5049-58.
99. Zhang J, Yang Y, Yang T, et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 2010; 103: 1215-20.
100. Nasser MW, Datta J, Nuovo G, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008; 283: 33394-405.
101. Zhou X, Richon VM, Wang AH, et al. Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. Proc Natl Acad Sci U S A. 2000; 97: 14329-33.
102. Qian DZ, Kachhap SK, Collis SJ, et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006; 66: 8814-21.
103. Bodily JM, Mehta KP, Laimins LA. Human Papillomavirus E7 enhances hypoxia-inducible factor 1 mediated transcription by inhibiting binding of histone deacetylases. Cancer Res. 2010; 73: 1187-95.
104. Seo HW, Kim EJ, Na H, et al. Transcriptional activation of hypoxia-inducible factor-1alpha by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1. FEBS Lett. 2009; 583: 55-60.
105. Kato H, Tamamizu-Kato S, Shibasaki F. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem. 2004; 279: 41966-74.
106. Lu J, McKinsey TA, Nicol RL, et al. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA. 2000; 97: 4070-5.
107. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003; 423: 349-55.
108. Kang JS, Alliston T, Delston R, et al. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J. 2005; 24: 2543-55.
109. Li H, Xie H, Liu W, et al. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest. 2009; 119: 3666-77.
110. Urbich C, Rossig L, Kaluza D, et al. HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood. 2009; 113: 5669-79.
111. Ha CH, Wang W, Jhun BS, et al. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J Biol Chem. 2008; 283: 14590-9.
112. Milde T, Oehme I, Korshunov A, et al. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 2010; 16: 3240-52.
113. Huang Y, Tan M, Gosink M, et al. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res. 2002; 62: 2913-22.
114. Roy S, Shor AC, Bagui TK, et al. Histone deacetylase 5 represses the transcription of cyclin D3. J Cell Biochem. 2008; 104: 2143-54.
115. Yarosh W, Barrientos T, Esmailpour T, et al. TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. Cancer Res. 2008; 68: 693-9.
116. Sun G, Yu RT, Evans RM, et al. Orphan nuclear receptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation. Proc Natl Acad Sci U S A. 2007; 104: 15282-7.
117. Sun G, Alzayady K, Stewart R, et al. Histone demethylase LSD1 regulates neural stem cell proliferation. Mol Cell Biol. 2010; 30: 1997-2005.
118. Ishikawa S, Nagai Y, Masuda T, et al. The role of oxysterol binding protein-related protein 5 in pancreatic cancer. Cancer Sci. 2010; 101: 898-905.
119. Dequiedt F, Kasler H, Fischle W, et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity. 2003; 18: 687-98.
120. Gao C, Cheng X, Lam M, et al. Signal-dependent regulation of transcription by histone deacetylase 7 involves recruitment to promyelocytic leukemia protein nuclear bodies. Mol Biol Cell. 2008; 19: 3020-7.
121. Mottet D, Bellahcene A, Pirotte S, et al. Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res. 2007; 101: 1237-46.
122. Jensen ED, Gopalakrishnan R, Westendorf JJ. Bone morphogenic protein 2 activates protein kinase D to regulate histone deacetylase 7 localization and repression of Runx2. J Biol Chem. 2009; 284: 2225-34.
123. Jensen ED, Schroeder TM, Bailey J, et al. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res. 2008; 23: 361-72.
124. Margariti A, Zampetaki A, Xiao Q, et al. Histone deacetylase 7 controls endothelial cell growth through modulation of beta-catenin. Circ Res. 2010; 106: 1202-11.
125. Malik S, Jiang S, Garee JP, et al. Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Mol Cell Biol. 2010; 30: 399-412.
126. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009; 280: 168-76.
127. Moreno DA, Scrideli CA, Cortez MA, et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol. 2010; 150: 665-73.
128. Dokmanovic M, Perez G, Xu W, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther. 2007; 6: 2525-34.
129. Duong V, Bret C, Altucci L, et al. Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res. 2008; 6: 1908-19.
130. Wen W, Ding J, Sun W, et al. Suppression of cyclin D1 by hypoxia-inducible factor-1viadirect mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res. 2010; 70: 2010-9.
131. Chen J, Fiskus W, Eaton K, et al. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood. 2009; 113: 4038-48.
132. Scott FL, Fuchs GJ, Boyd SE, et al. Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function. J Biol Chem. 2008; 283: 19499-510.
133. Rad R, Rad L, Wang W, et al. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science. 2010; 330: 1104-7.
134. Zhou X, Marks PA, Rifkind RA, et al. Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci U S A. 2001; 98: 10572-7.
135. Petrie K, Guidez F, Howell L, et al. The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem. 2003; 278: 16059-72.
136. Sparrow DB, Miska EA, Langley E, et al. MEF-2 function is modified by a novel co-repressor, MITR. EMBO J. 1999; 18: 5085-98.
137. Haberland M, Arnold MA, McAnally J, et al. Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol Cell Biol. 2007; 27: 518-25.
138. Mejat A, Ramond F, Bassel-Duby R, et al. Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat Neurosci. 2005; 8: 313-21.
139. Sugo N, Oshiro H, Takemura M, et al. Nucleocytoplasmic translocation of HDAC9 regulates gene expression and dendritic growth in developing cortical neurons. Eur J Neurosci. 2010; 31: 1521-32.
140. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007; 13: 1299-307.
141. Lucio-Eterovic AK, Cortez MA, Valera ET, et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer. 2008; 8: 243-52.
142. Wong RH, Chang I, Hudak CS, et al. A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell. 2009; 136: 1056-72.
143. Yuan Z, Peng L, Radhakrishnan R, et al. Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein. J Biol Chem. 2010; 285: 39329-38.
144. North BJ, Marshall BL, Borra MT, et al. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell. 2003; 11: 437-44.
145. Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 2002; 62: 4041-7.